Find Verified Medical Healthcare Suppliers, Manufacturers and Wholesalers

OVCHECK have secured a marker that can diagnose ovarian cancer with an accuracy of 95% or higher (sensitivity of 100% and specificity of 91%), and the project is currently in the clinical validation stage.

OVCHECK DEVELOPMENT PROCESS
Bertis is currently developing a highly accurate early ovarian cancer diagnosis technology with Seoul National University Hospital Gangnam Center.

The tumor markers CA125 and HE4, the conventional biomarker for ovarian cancer testing, have limitations in the early screening of ovarian cancer due to their low sensitivity and specificity.

Bertis is developing a technology that enables a more accurate diagnosis of ovarian cancer and is currently in the clinical verification stage by securing markers to diagnose ovarian cancer with more than 95% accuracy (100% sensitivity and 91% specificity).

PANCCHECK is a blood test solution that enables early diagnosis of pancreatic cancer with 94% accuracy is under development.

PANCCHECK DEVELOPMENT PROCESS:
While effective early diagnostic methods for pancreatic cancer are currently lacking, BERTIS is developing a technology that enables early diagnosis of pancreatic cancer with a small blood sample.

Through research, we have identified 10 protein biomarkers as a diagnostic marker panel for pancreatic cancer. Following algorithm development and validation, we have uncovered a combination of markers that demonstrates a high accuracy of 98% and is applicable in clinical settings.

Global proteomics (Cell, Tissue, blood proteome)
Label-free analysis based on data-independent acquisition (DIA). Our industry-leading protein analysis of non-depleted plasma can result in 1,300 protein identifications in one-hour per single sample.

Our isotope-labeling enables a sample-to-sample comparison analysis in protein quanti�cation. Bertis labeling quantification and advanced fractionation technology enable industry-leading protein quantification analysis in cell or tissue samples. Our phospho/glyco proteomics ensures high-quality post-translational modification (PTM) analysis of proteins, providing an optimized solution for biomarker discovery and mechanism of action analysis.

Our bioinformatics analysis provides your research needs from basic analysis of protein composition and quantiy cation to in-depth systems biology analysis. We provide analysis services that meet our customer's needs through continuous communication and interaction.

Companion Diagnostics (CDx) provide a companion diagnostic solution through pathway analysis based on RNA and protein quantification information respective to subtypes from each diseases.

For precision medicines developed based on multi-omics analysis, biomarkers can be used to identify target patients in advance. Global pharmaceutical companies are active in the use of companion diagnostics as a key strategic tool in clinical development programs.

PASS provides solutions for the entire process from discovery of drug candidates to non-clinical to clinical trials through pan-omics technology.

Bertis has array of innovative and reliable technology to increase the safety and efficacy of an investigational drug across the clinical research landscape, including solutions for the discovery of biomarkers for companion diagnostics and the determination of clinical targets through functional analysis.

Protein Characterization (Physicochemical property of proteins) structure analysis using mass spectrometry provides results that meet the requirements of the FDA, the MFDS and other regulatory authorities regarding novel therapies or biosimilars. Based on basic amino acid analysis (full sequencing), we perform post-translational modification (PTM) analysis, which is important for protein potency and stability. In this regard, we can perform test methods based on design of experiment (DOE) statistical methodology and deliver documents to be submitted to regulatory authorities.

Protein identification and quantification : Structural analysis of all types of protein therapeutics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and enzymes

- Full Length-Amino acids sequencing Peptide identification of each peak through peptide mapping (MS spectrum confirmation, MS/MS spectral analysis with 100% AA matches)
- Improved N- and C-terminal sequencing of proteins

Post-translational modification (PTM) : More reliable results based on design of experiment (DOE) statistical methodology to perform the experiments systematically and analyze data efficiently

- Disulfide bond analysis ID Total possible lankage analysis
- Deamidation identification and quantification
- Phosphorylation identification and quantification , phospho-proteomic analysis
- Other functional modifications

Glycomics : Single protein analysis and research of protein complexes with glycosylation closely related to biological function and toxicity as well as structural stability of proteins

- Glycosylation site determination
- Glycan profiling
- Site-specific glycan identification and quantification
- Glycomics research with glycan enrichment